Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Masitinib Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1048007-93-7, Masitinib (mesylate), Masivet, Ab-1010 mesylate, Masitinib mesilate, Ab 1010 mesylate
    Molecular Formula
    C29H34N6O4S2
    Molecular Weight
    594.8  g/mol
    InChI Key
    TXCWBWKVIZGWEQ-UHFFFAOYSA-N
    FDA UNII
    ZK89EG3A18
    Masitinib Mesylate is the orally bioavailable mesylate salt of masatinib, a multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Masitinib selectively binds to and inhibits both the wild-type and mutated forms of the stem cell factor receptor (c-Kit; SCFR); platelet-derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK). As a consequence, tumor cell proliferation may be inhibited in cancer cell types that overexpress these receptor tyrosine kinases (RTKs).
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide
    2.1.2 InChI
    InChI=1S/C28H30N6OS.CH4O3S/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34;1-5(2,3)4/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32);1H3,(H,2,3,4)
    2.1.3 InChI Key
    TXCWBWKVIZGWEQ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5.CS(=O)(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    ZK89EG3A18
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide

    2. Ab 1010

    3. Ab-1010

    4. Ab1010

    5. Kinavet

    6. Kinavet Ca-1

    7. Masatinib

    8. Masican

    9. Masitinib

    10. Masitinib Mesilate

    11. Masitinib Methanesulfonate

    12. Masivet

    13. Masiviera

    2.3.2 Depositor-Supplied Synonyms

    1. 1048007-93-7

    2. Masitinib (mesylate)

    3. Masivet

    4. Ab-1010 Mesylate

    5. Masitinib Mesilate

    6. Ab 1010 Mesylate

    7. Kinavet

    8. Zk89eg3a18

    9. Masican

    10. Masiviera

    11. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-pyridin-3-yl-1,3-thiazol-2-yl)amino)phenyl)benzamide Methanesulfonate

    12. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-pyridin-3-yl-1,3-thiazol-2-yl)amino)phenyl)benzamide Methanesulphonate

    13. 4-(4-methyl-piperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide Methanesulfonate

    14. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-thiazolyl)amino)phenyl)-, Methanesulfonate (1:1)

    15. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-thiazolyl)amino)phenyl)-, Methanesulphonate (1:1)

    16. 4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide Mesylate

    17. 928671-85-6

    18. Methanesulfonic Acid;4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide

    19. Unii-zk89eg3a18

    20. Masitinibmesylate

    21. Schembl1096348

    22. Dtxsid70146747

    23. Bcp30695

    24. Ex-a3996

    25. Masitinib Mesilate [who-dd]

    26. Yrb00793

    27. Hy-10209a

    28. Cs-1593

    29. Masitinib Mesylate [green Book]

    30. Masitinib Methanesulfonate [mi]

    31. Sb14845

    32. Ac-30896

    33. As-56731

    34. Ft-0707180

    35. C71194

    36. Masitinib Mesylate [ema Epar Veterinary]

    37. A927557

    38. Q27295645

    39. Ab1010 Mesylate;ab-1010 Mesylate;ab 1010 Mesylate

    40. Masitinib Mesylate Salt; Masitinib Mesilate;ab 1010 Mesylate Pound>>ab1010 Mesylate Pound>>ab-1010 Mesylate

    41. N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide Methanesulfonate

    42. N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide Methanesulfonate;

    2.4 Create Date
    2008-11-17
    3 Chemical and Physical Properties
    Molecular Weight 594.8 g/mol
    Molecular Formula C29H34N6O4S2
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count10
    Rotatable Bond Count7
    Exact Mass594.20829593 g/mol
    Monoisotopic Mass594.20829593 g/mol
    Topological Polar Surface Area164 Ų
    Heavy Atom Count41
    Formal Charge0
    Complexity788
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of amyotrophic lateral sclerosis.

    Treatment of mastocytosis

    Treatment of non resectable locally advanced or metastatic pancreatic cancer

    Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST)

    Treatment of non-resectable dog mast-cell tumours (grade 2 or 3) with confirmed mutated c-KIT tyrosine-kinase receptor.

    Treatment of mastocytosis

    Treatment of gastro-intestinal stromal tumours

    Treatment of amyotrophic lateral sclerosis

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    L01XE22

    L01XE22

    L01XE

    L01XE

    QL01XE90